In addition, the study found that in the mouse GVHD model, XY-52 (Compound 32) can effectively reduce the expression level of sST2, reduce the severity of GVHD, and improve the survival rate, and the differential intervention of ST2 antibody can also improve the survival rate of the GVHD mouse model. This evidence concerns the gene IL1RL1 and graft versus host disease.